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OBJECTIVES We sought to ascertain whether myocardial scarring occurs in living unselected patients with
hypertrophic cardiomyopathy (HCM).
BACKGROUND Myocardial scarring is known to occur in select HCM patients, who were highly symptomatic
prior to death or who died suddenly. The majority of HCM patients, however, are minimally
symptomatic and have not suffered sudden death.
METHODS Cine and gadolinium-enhanced magnetic resonance imaging was performed in 21 HCM
patients who were predominantly asymptomatic. Gadolinium hyperenhancement was as-
sumed to represent myocardial scar, and the extent of scar was compared to left ventricular
(LV) morphology and function.
RESULTS Scarring was present in 17 patients (81%). Scarring occurred only in hypertrophied regions
(10 mm), was patchy with multiple foci, and predominantly involved the middle third of the
ventricular wall. All 17 patients had scarring at the junction of the interventricular septum and
the right ventricular (RV) free wall. On a regional basis, the extent of scarring correlated
positively with wall thickness (r  0.36, p  0.0001), and inversely with wall thickening (r 
0.21, p 0.0001). On a per patient basis, the extent of scarring (mean, 8 9% of LV mass)
was minimally related to maximum wall thickness (r  0.40, p  0.07) and LV mass (r 
0.33, p  0.15), and correlated inversely with ejection fraction (r  0.46, p  0.04).
CONCLUSIONS Myocardial scarring is common in asymptomatic or mildly symptomatic HCM patients who
have not suffered sudden death. When present, scarring occurs in hypertrophied regions, is
consistently localized to the junctions of the septum and RV free wall, and correlates
positively with regional hypertrophy and inversely with regional contraction. (J Am Coll
Cardiol 2002;40:2156–64) © 2002 by the American College of Cardiology Foundation
It has recently been established that ventricular tachycardia
or fibrillation is the principal mechanism of sudden death in
patients with hypertrophic cardiomyopathy (HCM) (1). An
important anatomic component of the arrhythmogenic sub-
strate has been postulated to be myocardial replacement
scarring (2,3). Several necropsy studies have demonstrated
that myocardial scarring is common in patients with HCM,
even in the absence of angiographically significant epicardial
coronary disease (3–7). This finding, however, may not be
applicable to the overall population with HCM since the
patients assessed in these studies were generally highly
selected with severe symptoms of heart failure prior to
death, a group not representative of the majority of patients
with HCM. It is now recognized that most individuals with
HCM are asymptomatic or mildly symptomatic and have a
predominantly benign clinical course (8–12). Notwith-
standing this overall favorable prognostic profile, a small
subset of patients experience sudden death as the first
manifestation of HCM (3,9,12,13). Limited data from
post-mortem studies that have included subgroups of pa-
tients with HCM who were asymptomatic prior to death,
suggest that scarring is common in these patients as well
(3,13). It is unknown whether myocardial scarring occurs in
unselected patients with HCM who have not experienced
sudden death.
Gadolinium contrast-enhanced magnetic resonance im-
aging (MRI) is a new technique that allows visualization of
both transmural and subendocardial myocardial scarring
(14). This technique has been validated in patients with
documented chronic myocardial infarction, as well as in
animal models of infarct healing (14–16). Contrast MRI
has the unique advantage of allowing visualization of even
microinfarcts that cannot be detected by other noninvasive
imaging techniques (17).
The aim of the present study was to determine whether
myocardial scarring is present in HCM patients with mild
or no symptoms who are representative of the majority of
community patients with this disease.
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METHODS
Patient population. Twenty-one patients with HCM were
recruited between July 2000 and February 2001. All gave
informed consent to the protocol, which was approved by
the Northwestern Institutional Review Board. HCM was
diagnosed by the presence of a nondilated and hypertro-
phied left ventricle on two-dimensional echocardiography
(maximal wall thickness 15 mm in adult index patients or
13 mm in adult relatives of a HCM patient) in the
absence of another disease that could account for the
hypertrophy (9,18). Patients who were known to have aortic
stenosis, amyloidosis, or systemic hypertension were not
included. The median time between echocardiography and
MRI was six months (longest interval, three years). Sixty-
one consecutive patients were initially identified for enroll-
ment, but patients were excluded if they had concomitant
coronary artery disease (CAD) or history of myocardial
infarction (n  1), left ventricular (LV) systolic dysfunction
(n  1), implantation of a pacemaker or defibrillator (n 
23), refused to participate (n  6), or were lost to follow-up
(n  9).
Of the 21 study patients, 4 were50 years old. CAD was
excluded by angiographically normal coronary arteries in 3
of these 4. The remaining patient did not have angina or
other symptoms indicative of CAD. Of the 17 patients50
years, none had CAD risk factors except 2 in whom CAD
was excluded by angiography in 1 and stress nuclear imaging
in the other.
MRI protocol. All images were acquired on a 1.5T scanner
(Siemens Sonata) using a phased array receiver coil during
breath-holds (8 s) gated to the electrocardiogram. Cine
images were acquired in multiple short-axis and 2 to 3
long-axis views using TrueFISP (19). Short-axis views were
obtained every centimeter throughout the entire left ventri-
cle (20). A gadolinium-based contrast agent (gadoteridol,
0.1 mmol/kg) (17) was then administered intravenously,
and contrast-enhanced images were acquired in the same
views used for cine MRI 10 min after contrast administration.
Contrast-enhanced images were acquired using a segmented
inversion-recovery sequence, which has been described previ-
ously (21). The examination time was 30 to 40 min.
Analysis. For all patients, the MRI scans were placed in
random order after the identity markers were removed. The
cine and contrast-enhanced images were evaluated sepa-
rately by the consensus of two observers who were unaware
of the results of the other modality. Hyperenhanced tissue
on the contrast-enhanced images was assumed to represent
scarred myocardium (14).
Global parameters. The endocardial and epicardial bor-
ders of the myocardium were planimetered on the short-axis
cine images. Volumes were derived by summation of discs
and the ejection fraction calculated accordingly. The LV
mass was calculated by subtracting endocardial from epicar-
dial volume at end-diastole and multiplying by 1.05 g/cm3.
Systolic anterior motion of the mitral valve (SAM) was
assessed visually using the long-axis cine images through the
left ventricular outflow tract (LVOT) and graded as mild
(approached septum without contact), moderate (brief septal
contact), or severe (septal contact, 30% of systole) (22).
The extent of hyperenhanced myocardium was planime-
tered on the short-axis contrast-enhanced images (Fig. 1)
using an image intensity level 2 SD above the mean of
remote myocardium to define hyperenhancement and
threshold the image by computer (15).
Segmental model. Regional parameters were assessed us-
ing a model in which each short-axis view (6 to 10 per
patient) was divided into 36 circumferential segments (Fig.
1). For each segment on the cine images, LV end-diastolic
wall thickness and systolic wall thickening were measured
using the NIH Image program. For each segment on the
contrast-enhanced images, the extent of scar was expressed
as a percentage of the total segment area as well as a
percentage of the area of the outer, middle, and inner third
of the segment.
Clinical indexes. In all patients the peak instantaneous
LVOT gradient (mm Hg) was measured by continuous-
wave Doppler under basal conditions from the diagnostic
echocardiogram. The QT interval was measured from the
12-lead electrocardiogram nearest in time to the MRI
examination (median time difference, one month) and then
corrected using Bazett’s formula (23).
Statistical analysis. Continuous data are expressed as
mean  SD except where specified. The relationships
between continuous variables were examined by least-
squares linear regression analysis. To account for the non-
independence of the segmental data, a repeated-measures
variable for the patient was added to the linear regression
analysis using a mixed-effects model (S-PLUS 2000 soft-
ware) (24). Comparisons in the extent of scar between
segmental thickness and thickening subgroups were made
using one-way ANOVA; the Tukey method was used for
assessing pair-wise differences between the subgroups. All
statistical tests were two-tailed; p  0.05 was regarded as
statistically significant.
RESULTS
Patient characteristics. The clinical features are summa-
rized in Table 1. The age ranged from 18 to 76 years
(median, 39 years). There were 12 men and 9 women. Of
the 21 patients, 20 (95%) were asymptomatic or had only
Abbreviations and Acronyms
CAD  coronary artery disease
HCM  hypertrophic cardiomyopathy
LV  left ventricular
LVOT  left ventricular outflow tract
MRI  magnetic resonance imaging
RV  right ventricular
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mild symptoms (New York Heart Association class I or II)
at the time of enrollment. In the majority of patients (62%),
the primary reason for the initial echocardiogram was family
screening or the finding of an asymptomatic murmur on
routine physical examination. Of the remaining patients,
two underwent evaluation for chest pain, two for syncope,
and four for exertional dyspnea. No patient had a family
history of sudden cardiac death as defined previously (18).
The pattern of LV hypertrophy by echocardiography was
asymmetric septal hypertrophy (thickness of septum/free
wall 1.3) (25) in 18 patients (86%), concentric in two and
apical in one. Two patients had maximum wall thickness
13 mm by MRI. Both patients had maximum wall
thickness 13 mm on their respective diagnostic echocar-
diograms (i.e., both met the entrance criteria in the Meth-
ods section). Resting LVOT obstruction (peak instanta-
neous gradient 30 mm Hg) was present in eight patients
(38%). Of the 18 patients who had Holter monitoring, 4
had evidence of episodic ST segment depression (all asymp-
tomatic), and none had evidence of supraventricular or
ventricular tachycardia (3 consecutive beats).
MRI. Figures 1 and 2 show typical examples of images
obtained by MRI. For the full-motion cines video cor-
responding to Figure 2, please see the December 18th
issue of JACC online at www.cardiosource.com/jacc.html.
The LV ejection fraction averaged 70  11% (range, 40%
to 85%), the LV mass ranged from 95 to 427 g (mean,
238  88 g), and the maximal end-diastolic wall thick-
ness ranged from 11 to 37 mm (mean, 25  8 mm).
Twelve patients exhibited SAM (Fig. 2 full-motion cine
for Patient 19). The contrast images demonstrated myo-
cardial hyperenhancement representing scar tissue in 17
of the 21 patients (81%). In general, scarring occurred in
a patchy distribution with multiple discrete foci within
hypertrophied regions of the interventricular septum and
the anterior and posterior walls (Figs. 1 and 2). Scarring
was not present in the lateral free wall. Of the 17 patients
with scars, 16 (94%) had two or more foci of scarring.
The mass of scar tissue ranged from 0 to 143 g (mean, 22
 31 g), and was on average 8  9% of the LV mass.
Regional scarring, wall thickness, and wall thickening. In a
total of 4,912 matched segments (no unmatched segments),
the extent of scar tissue was compared to wall thickness at
end-diastole. Scarring was present in 839 segments (17%).
The average end-diastolic wall thickness was 13.4 
6.1 mm (maximum, 37 mm). There was a modest but
significant correlation between the extent of scarring and
the end-diastolic wall thickness (r  0.36, p  0.0001).
This relationship remained significant (p 0.005) when the
data were reanalyzed with a separate parameter for “patient”
to account for the nonindependence of segments. When the
segments were divided into subgroups according to end-
diastolic wall thickness (18,26), the mean scar extent in-
creased significantly and progressively in direct relation to
wall thickness (p  0.05 for every pair-wise comparison
Figure 1. Typical images obtained by magnetic resonance imaging (MRI) with superimposed segmental model. Segments were analyzed for diastolic wall
thickness, systolic wall thickening, and the spatial extent of scar represented by hyperenhanced myocardium (outlined regions).
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using the Tukey method, Fig. 3). None of the 1,638
segments 10 mm in thickness had any scarring.
The extent of scar tissue and the end-diastolic wall
thickness were also compared to systolic wall thickening in
3,578 matched segments (fewer segments due to base-apex
shortening). The average systolic thickening was 77  63%
of the end-diastolic thickness. Both the extent of scar tissue
and the end-diastolic thickness showed a negative correla-
tion with systolic thickening (r  0.21, p  0.0001, and
r  0.55, p  0.0001, respectively). These relationships
remained significant (p  0.05 and p  0.0001, respec-
tively) when the data were reanalyzed to account for the
nonindependance of segments. There was a progressive
decrease in mean scar extent with each increment in systolic
thickening (p  0.05 for every pair-wise comparison using
the Tukey method, Fig. 3). When absolute rather than
fractional thickening was considered, there was still a
significant negative correlation with the extent of scar tissue
and the end-diastolic thickness (r0.16, p 0.0001 and
r  0.20, p  0.0001, respectively; p  0.05 and p 
0.0001, respectively, accounting for nonindependence of
segments). The results were similar when the analysis was
repeated using a 12-segment rather than a 36-segment
model for the short-axis slices (r  0.17, p  0.0001, and
r  0.18, p  0.0001, respectively; p  0.07 and p 
0.001, respectively, accounting for nonindependence of
segments).
The mean values for end-diastolic wall thickness, wall
thickening, and scar extent (hyperenhancement) are repre-
sented as grey-scale maps in Figure 4. These maps represent
the averaged segmental data for all patients. For the map of
scar tissue, segments were further divided into outer, mid-
dle, and inner thirds. Figure 4 demonstrates that the lateral
free wall and the ventricular apex were least likely to be
hypertrophied. These regions had the greatest amount of
systolic thickening and the least amount of scar tissue.
Hypertrophied regions did not have a uniform transmural
distribution of scarring; the mid-myocardium had the great-
est amount of scarring which consistently involved the
junctions of the interventricular septum and the RV free
wall. All 17 patients with scars had scarring of either the
anteroseptal junction or the inferoseptal junction and 16 had
scarring of both junctions.
Extent of scarring related to global parameters. Figure 5
demonstrates that the extent of scar (hyperenhancement) as
a percentage of the left ventricle correlated poorly with the
maximum LV end-diastolic wall thickness (r  0.40, p 
0.07) and the LV mass (r  0.33, p  0.15), and modestly
with the LV ejection fraction (r0.46, p 0.04). When
the patient with the depressed EF on MRI (Patient #18)
was removed from the analysis the relationships did not
change significantly (wall thickness: r  0.40, p  0.08;
mass: r  0.34, p  0.15; EF: r  0.55, p  0.01). There
was a positive correlation with the corrected QT-interval
(r  0.47, p  0.03). No relation was observed to the
LVOT gradient (p  0.82) or to the degree of SAM (p 
0.29).
Table 1. Clinical Characteristics








SAM MWT (mm) HE (%LV)
1 28 F I none ASH 25 412 STD none 20 21
2 54 M I none concentric 49 444 normal mild 27 12
3 19 M I none ASH 25 462 normal none 36 33
4 39 F I none ASH 30 480 normal none 26 22
5 76 F II D ASH 36 505 STD moderate 21 10
6 44 M I none ASH 58 400 STD moderate 33 4
7 47 M I none ASH 25 404 – none 12 none
8 64 F II D ASH 25 413 normal none 22 11
9 18 M I none ASH 25 413 normal none 11 none
10 47 F III CP,D ASH 25 490 – none 23 9
11 28 F I syncope ASH 25 445 – mild 29 6
12 39 F I none ASH 49 400 normal moderate 27 6
13 72 M II D ASH 41 408 normal moderate 23 2
14 41 M I CP Apical 25 409 normal none 18 none
15 38 F I none ASH 36 440 normal moderate 19 4
16 35 F I none ASH 25 380 normal none 13 none
17 34 M I none ASH 36 400 STD mild 37 3
18 48 M II D ASH 29 520 normal mild 26 11
19 41 M I none concentric 25 447 normal mild 27 8
20 22 M I none ASH 48 429 normal moderate 33 10
21 39 M II syncope,D ASH 25 416 normal mild 32 4
*From echocardiogram; †Peak instantaneous gradient (mm Hg) by continuous-wave doppler echocardiography under basal conditions.
ASH  asymmetric septal hypertrophy (thickness of septum/free wall 1.3); CP  chest pain; D  dyspnea; HE  hyperenhancement; LVOT  left ventricular outflow
tract; MRI  magnetic resonance imaging; MWT  maximum wall thickness; NYHA  New York Heart Association functional class; %LV  percent left ventricular mass;
QTc  corrected QT interval on 12-lead electrocardiogram; SAM  systolic anterior motion of mitral valve (see text for grading system); STD  ST-segment depression.
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DISCUSSION
Myocardial scarring in HCM. In the present study, we
observed that myocardial scarring is a common finding in
patients with HCM. Prior studies have also documented
scarring in vivo, but these were invasive, requiring tissue
samples from myocardial biopsy or surgical myomectomy in
patients with refractory symptoms (27,28). The remainder
of the studies that have documented scarring were necropsy
studies (3–7,29,30) or studies of explanted hearts (31). In
comparison to previous studies reporting myocardial scar-
ring, the patients in the present study are a unique popula-
tion, in so far as they are predominantly asymptomatic,
belong to an unselected community cohort and have not
experienced sudden death. These patients are likely to be
representative of the majority of patients with HCM.
We observed a peculiar pattern of myocardial scarring.
The scarring occurred only in hypertrophied regions, was
patchy with multiple foci, and predominantly involved the
mid-ventricular wall (Figs. 2 and 4). The location of
scarring did not correspond to the perfusion territories of
the epicardial coronary arteries. Maron and coworkers (4) in
a necropsy study, also noted that scarring did not correspond
to any particular epicardial coronary artery distribution. In a
follow up study (5), they reported increased numbers of
structurally abnormal intramural coronary arteries within
areas of scarred myocardium. They postulated a causal role
for these intramural arteries in producing myocardial isch-
emia leading to scarring.
In our study, the pattern of scarring was also character-
ized by consistent involvement of the junctions of the
Figure 2. Representative patient images. (A) Patient with asymmetric septal hypertrophy, maximum wall thickness of 20 mm, normal ejection fraction, and
marked myocardial scarring (hyperenhancement shown by arrows). (B) Patient with greater hypertrophy (maximum wall thickness, 27 mm) but with less
scarring. In both patients, there are multiple foci of scar, which are predominantly mid-myocardial in location and are not present in the lateral free wall.
The long-axis cines images of Patient 19 demonstrate systolic anterior motion of the mitral valve, systolic flow turbulence in the left ventricular outflow
tract, and mitral regurgitation. For the accompanying full-motion cines video corresponding to Figure 2, please see the December 18 issue of JACC at
www.cardiosource.com/jacc.html.
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interventricular septum and the right ventricular free wall.
All 17 patients with scars had scarring of either the
anteroseptal junction or the inferoseptal junction, and 16
had scarring of both junctions. Although systematically
examined in only one report (29), the presence of scarring in
these particular junctional locations have been demonstrated
incidentally in several necropsy studies (3,6,7). Kuribayashi
and Roberts (29) demonstrated in a necropsy study of
HCM that the junctions of the septum and RV free wall are
also where myocardial fascicular disarray is maximal, asso-
ciated with numerous deep tissue clefts, and destruction of
the normal circular architecture of the midwall muscle layer.
The current study demonstrates in living patients with
HCM, a pattern of myocardial scarring that has been
observed previously only in HCM patients after death.
Correlates of scarring. The only morphologic feature of
HCM found to be predictive of future sudden death is the
magnitude of LV hypertrophy (18,32). Recently Basso et al.
(3) reported a positive correlation between the magnitude of
septal hypertrophy and the extent of replacement scarring in
young patients with HCM experiencing sudden death.
They concluded that the presence of scarring supports the
clinical evidence (33) that ischemia occurs in the natural
history of HCM and may contribute to life-threatening
electrical instability. Consistent with the findings of Basso
et al. (3) the current study found that the extent of scar
increased significantly and progressively in direct relation to
wall thickness on a regional basis (Fig. 3). On a per patient
basis, however, the extent of scarring was only minimally
related to the maximum LV wall thickness (Fig. 5). Al-
though it is possible that this relation may have reached
statistical significance with a larger study population, it is
clear from the current data that there is not a one-to-one
relationship between scar extent and wall thickness. First,
there is the predilection of scarring for the junctions of the
septum and RV free wall. These regions, while hyper-
trophied, did not represent the location of maximum wall
thickness (Fig. 4). Second, there is a large variation in the
amount of scarring in hypertrophied regions on both a
regional and per patient basis. For example, among the five
patients with maximum wall thickness 30 mm, the
amount of scar ranged from 3% to 33% of the total LV
mass. Likewise, Figure 2 demonstrates a patient with a large
amount of scarring and relatively less hypertrophy (Fig. 2A)
in comparison to another patient with less scarring yet
greater hypertrophy (Fig. 2B). Despite these observations,
there is nonetheless an association between scar and wall
thickness. None of the 1,638 segments that were less than
10 mm in thickness had any scarring, and the four patients
who did not have any scarring, were those with the least
maximum wall thickness of the entire cohort (Fig. 5).
In the current study, regional systolic dysfunction was
observed (Fig. 4) despite overall normal to supranormal LV
ejection fraction in the patient cohort. This finding is
consistent with the results of several studies in patients with
HCM (34–37). Potential mechanisms for regional systolic
dysfunction in HCM that have been postulated include
primary defects of the sarcomeric proteins leading to im-
paired myocyte contractility, increased interstitial fibrosis
leading to impaired myocardial shortening, and disorga-
nized arrangement of the myocytes leading to inefficient,
nonuniform contraction (36,38). Our results indicate an
additional possible mechanism. We found that the mean
extent of scar increased significantly and progressively as
wall thickening decreased (Fig. 3). This was observed for all
regions of the left ventricle (Fig. 4). Accordingly, a causal
role for myocardial scarring in producing regional dysfunc-
tion should be considered.
Study limitations. The use of gadolinium enhanced MRI
to detect myocardial scarring has been validated in animal
models of ischemic injury and in patients with coronary
artery disease (14–16). However, the direct comparison of
gadolinium MRI to the underlying histopathology has not
yet been performed in the case of hypertrophic cardio-
Figure 3. Relationship between amount of scarring (% hyperenhancement of segment) and segmental wall thickness and thickening. The amount of scarring
increases progressively in direct relation to wall thickness and in inverse relation to wall thickening (p  0.05 for every pairwise comparison between
increments in both thickness and thickening). Error bars represent standard error of the mean. The number of segments for each category are listed.
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myopathy. The interpretation, therefore, that gadolinium
hyperenhancement solely represents myocardial scarring is
speculative. Other types of fibrosis such as interstitial
fibrosis may also lead to an increased distribution volume of
gadolinium within the myocardium and thus also produce
hyperenhancement. Furthermore, the presence of hyper-
enhancement, even if scarring is verified, should not be
equated with the process of ischemic myocardial necrosis as
scarring may be due to a variety of mechanisms other than
ischemia.
Clinical implications. Data from recent epidemiological
studies indicate that the overall risk of sudden death in our
patient population is likely to be 1% per year (8–12).
Since scarring was present in over 80% of our patients, the
presence of scarring in itself cannot be indicative of an
adverse prognosis. However, the total amount of scarring
may be a prognostic determinant. Tanaka et al. (39)
quantified the amount of myocardial scarring in a necropsy
study of 10 patients with HCM. Although the sample size
was small, they found that all seven patients who died
suddenly had a larger amount of scarring (13  3% of total
area) than the three who died from noncardiac causes (6 
3%, p  0.05). Additional evidence that suggests a relation
between the amount of scarring and future adverse events is
our finding of a positive correlation between the amount of
scarring and the magnitude of hypertrophy, since it has been
demonstrated that the magnitude of hypertrophy is related
to the risk of sudden death (18,32). The mechanism by
which LV hypertrophy relates to higher risk for malignant
ventricular arrhythmias and sudden death is unknown. The
results of the current study, however, raise the possibility
that myocardial scarring is a potential link between LV
hypertrophy and the occurrence of sudden death.
Using similar criteria as the study by Tanaka et al. (39),
three of the patients in the present study would be deemed
to be at higher risk (15% scar). However, extreme hyper-
trophy (30 mm), which has been shown to be an impor-
tant risk factor for sudden death (18), was present in only
one of these three patients (Patient 3). Patients 1 and 4, who
had significant scarring without extreme hypertrophy, high-
Figure 4. Spatial distribution of the mean values for segmental wall thickness, wall thickening and scar extent (hyperenhancement) represented as grey-scale
maps in basal, mid, and apical short-axis slices in all patients. Note that the thicker walls (basal and mid septum) have the least thickening. Scarring
predominantly involves the mid-wall myocardium at the junctions of the interventricular septum and the right ventricular free wall (arrows).
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lights the important finding of Elliott et al. (26) who
recently reported that most sudden deaths in HCM occur in
patients with wall thickness 30 mm, and concluded that
the presence of mild hypertrophy cannot be used to reassure
patients that they are at low risk. Whether extreme myo-
cardial scarring is an independent predictor of adverse
prognosis or adds incremental prognostic information to the
magnitude of LV hypertrophy remains to be determined.
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